Abbott Laboratories vs. Arcutis Biotherapeutics, Inc. Common Stock
ABT
Abbott Laboratories
$102.98 +0.36%
VS ARQTArcutis Biotherapeutics, Inc. Common Stock
$24.25 +1.53%
Abbott Laboratories (ABT) comes out ahead, leading on 7 of 9 compared factors.
Size & Scale
| ABT | ARQT | |
|---|---|---|
| Market Cap | $177.55 billion | $3.00 billion |
| Revenue (TTM) | $46.59 billion | $463.98 million |
| Net Income (TTM) | $5.42 billion | $28.52 million |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | ARQT | |
|---|---|---|
| P/E Ratio | 33.33 | 115.48 |
| Price / Book | 3.43 | 13.61 |
| Price / Sales | 3.81 | 6.47 |
ABT leads on 3 of 3 valuation factors.
Profitability
| ABT | ARQT | |
|---|---|---|
| Net Margin | 11.65% | 6.15% |
| Return on Equity | 10.48% | 12.93% |
ABT and ARQT split the profitability factors evenly.
Dividend
| ABT | ARQT | |
|---|---|---|
| Dividend Yield | 2.45% | — |
| Payout Ratio | 81.55 | — |
ABT and ARQT split the dividend factors evenly.
Risk & Sentiment
| ABT | ARQT | |
|---|---|---|
| Short Interest | 0.57% | 0.19% |
ARQT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, ARQT overview, ARQT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.